1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Infecciosas

Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Albóniga OE, Moreno E, Martínez-Sanz J, Vizcarra P, Ron R, Díaz-Álvarez J, Rosas M, Sánchez-Conde M, Galán JC, Angulo S, Moreno S, Barbas C, Serrano-Villar S.

    Differential abundance of lipids and metabolites related to SARS-CoV-2 infection and susceptibility.

    SCIENTIFIC REPORTS . 13(1): 15124-15124. Nº de citas: 7

    [doi:10.1038/s41598-023-40999-5]

  • Perez-Molina JA, Cancio-Suárez MR, Moreno S.

    Is It Time for Treatment as Prevention of Chronic Hepatitis B?

    PATHOGENS . 12(9): . Nº de citas: 1

    [doi:10.3390/pathogens12091137]

  • Baca R, Vivancos-Gallego MJ.

    Interferon-gamma release assay for the diagnosis of latent tuberculosis infection in the prison population with a positive tuberculin test: a descriptive study in a prison (Burgos, Spain).

    Revista española de sanidad penitenciaria . 25(3): 104-111.

    [doi:10.18176/resp.00076]

  • de la Torre Tarazona, Erick, Jimenez, Daniel, Marcos-Mencia, Daniel, Mendieta-Baro, Alejandro, Rivera-Delgado, Alejandro, Romero-Hernandez, Beatriz, Muriel, Alfonso, Rodriguez-Dominguez, Mario, Serrano-Villar, Sergio, Moreno, Santiago.

    The Influence of Pre-Existing Immunity against Human Common Cold Coronaviruses on COVID-19 Susceptibility and Severity

    Microbiology Research . 14(3): 1364-1375.

    [doi:10.3390/microbiolres14030093]

  • Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masiá M, Fanciulli C, Hernández C, Lagarde M, Gutierrez A, Curran A, Morano L, Montero-Alonso M, Troya J, Rigo R, Casadellà M, Navarro-Alcaraz A, Ardila F, Parera M, Bernal E, Echeverria P, Estrada V, Hidalgo-Tenorio C, Macias J, Prieto P, Portilla J, Valencia E, Vivancos MJ, Rivero A.

    Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

    The Journal of antimicrobial chemotherapy . 78: 2696-2701. Nº de citas: 4

    [doi:10.1093/jac/dkad285]

  • Martínez-Sanz J, Díaz-Álvarez J, Rosas M, Ron R, Iribarren JA, Bernal E, Gutiérrez F, Ruiz Sancho A, Cabello N, Olalla J, Moreno S, Serrano-Villar S.

    Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events.

    EBioMedicine . 95: 104773-104773. Nº de citas: 16

    [doi:10.1016/j.ebiom.2023.104773]

  • San Martín-López JV, Mesa N, Bernal-Bello D, Morales-Ortega A, Rivilla M, Guerrero M, Calderón R, Farfán AI, Rivas L, Soria G, Izquierdo A, Madroñal E, Duarte M, Piedrabuena S, Toledano-Macías M, Marrero J, de Ancos C, Frutos B, Cristóbal R, Velázquez L, Mora B, Cuenca P, Satué JÁ, Ayala-Larrañaga I, Carpintero L, Lara C, Llerena ÁR, García V, García de Viedma V, Prieto S, González-Pereira N, Bravo C, Mariño C, Lechuga LA, Tarancón J, Gonzalo S, Moreno S, Ruiz-Giardin JM.

    Seven Epidemic Waves of COVID-19 in a Hospital in Madrid: Analysis of Severity and Associated Factors.

    VIRUSES-BASEL . 15(9): . Nº de citas: 6

    [doi:10.3390/v15091839]

  • Sánchez-Conde M, Alba C, Castro I, Dronda F, Ramírez M, Arroyo R, Moreno S, Rodríguez JM, Brañas F.

    Comparison of the Fecal Bacteriome of HIV-Positive and HIV-Negative Older Adults.

    Biomedicines . 11(8): . Nº de citas: 3

    [doi:10.3390/biomedicines11082305]

  • Espineira S, Flores-Piñas M, Chafino S, Viladés C, Negredo E, Fernández-Arroyo S, Mallolas J, Villar B, Moreno S, Vidal F, Rull A, Peraire J.

    Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV.

    Frontiers in immunology . 14: 1228795-1228795. Nº de citas: 9

    [doi:10.3389/fimmu.2023.1228795]

  • Hernando V, Suárez L, Gutiérrez G, López JC, Navarro-Soler R, Cabello A, Sanz J, Suarez-García I, Fernández MT, Losa JE, Pérez JL, Ramos-Ruperto L, Pérez-Elías MJ, Aayuni WBCE, Cuesta M, González G, Izquierdo A, Viloria L, López I, Martínez E, Castrillejo D, Jaume Amengual MG, Belmonte MA, Arraiza A, de la Torre J, Miqueleiz E, Marcos H, Ruiz-Algueró M, Villegas T, Simón L, Diaz A.

    Vaccination trends in people with HIV infection participanting in the hospital-based survey of patients infected with HIV, 2006-2021.

    Enfermedades Infecciosas Y Microbiologia Clinica (english Ed.) . : .

    [doi:10.1016/j.eimce.2023.07.006]

  • Berna-Rico E, Chamorro-Tojeiro S, Pérez-González A, Pérez-García B.

    Superinfected scabies.

    MEDICINA CLINICA . 162(3): 145-145.

    [doi:10.1016/j.medcli.2023.06.048]

  • Norman FF, Gonzalez-Sanz M, Gullón-Peña B, Chamorro-Tojeiro S, Rosas M, Crespillo-Andujar C, Monge-Maillo B, Comeche B, Corbacho-Loarte MD, Arcas C, Peña I, Tenorio MC, Lopez-Vélez R, Pérez-Molina JA.

    Haemoglobinopathies in mobile populations from sub-Saharan Africa

    JOURNAL OF TRAVEL MEDICINE . 30: .

    [doi:10.1093/jtm/taad115]

  • Moreno S, Rivero A, Ventayol P, Falcó V, Torralba M, Schroeder M, Neches V, Vallejo-Aparicio LA, Mackenzie I, Turner M, Harrison C.

    Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.

    Infectious diseases and therapy . 12(8): 2039-2055. Nº de citas: 10

    [doi:10.1007/s40121-023-00840-y]

  • Palacios R, Gómez-Ayerbe C, Casado JL, Tejerina F, Montes ML, Castaño M, Ocampo A, Rial D, Ribera E, Galindo MJ, Hidalgo C, Fariñas C, Montero M, Payeras T, Fanjul F, de la Torre J, Santos J.

    Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119

    HIV MEDICINE . 24(8): 933-937. Nº de citas: 4

    [doi:10.1111/hiv.13489]

  • Pérez-Molina JA, Crespillo-Andújar C, Trigo E, Chamorro S, Arsuaga M, Olavarrieta L, Navia B, Martín O, Monge-Maillo B, Norman FF, Lanza VF, Serrano-Villar S.

    Chagas disease is related to structural changes of the gut microbiota in adults with chronic infection (TRIPOBIOME Study).

    PLOS NEGLECTED TROPICAL DISEASES . 17(7): . Nº de citas: 5

    [doi:10.1371/journal.pntd.0011490]

  • Barbero Allende JM, Gómez-Junyent J, Sorlí Redó L, Rodríguez-Pardo D, Murillo Rubio Ó, Fernández Sampedro M, Escudero-Sánchez R, García Gutiérrez M, Portillo ME, Sancho I, Rico Nieto A, Guio Carrión L, Soriano A, Morata Ruiz L.

    Description of reinfection of joint prosthesis after 2-stage replacement (infection of the 2nd stage prosthesis): A multicenter study.

    Enfermedades Infecciosas Y Microbiologia Clinica (english Ed.) . : .

    [doi:10.1016/j.eimce.2023.07.002]

  • Serrano-Villar S, Tincati C, Raju SC, Sáenz JS, Moreno E, Bargiela R, Cabello-Ubeda A, Sendagorta E, Kurz A, Perez Molina JA, de Benito A, Hov JR, Fernandez-Lopez L, Muriel A, Del Campo R, Moreno S, Trøseid M, Seifert J, Ferrer M.

    Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.

    NATURE MEDICINE . 29(7): 1738-1749. Nº de citas: 15

    [doi:10.1038/s41591-023-02407-3]

  • Rosas Cancio-Suárez M, Díaz-Álvarez J, Ron R, Martínez-Sanz J, Serrano-Villar S, Moreno S, Sánchez-Conde M.

    From Innovation to Implementation: The Evolution of HIV Pre-Exposure Prophylaxis and Future Implications.

    PATHOGENS . 12(7): . Nº de citas: 4

    [doi:10.3390/pathogens12070924]